Medication info
RANIGLIPTIN Duo Sustained Release Tablet 5/1000 mg (Lina-gliptin, Metformin Hydrochloride)

RANIGLIPTIN Duo Sustained Release Tablet 5/1000 mg (Lina-gliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Aliko Pharmaceutical Co., Ltd.
Appearance
Oval sustained release tablet, white to almost white, engraved with A501 on one side
Packaging
28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle
Approval status
Active

MFDS item code 202400514 · Approved 2024.03.12 · Insurance code 656005540

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and extended-release metformin hydrochloride 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse effects associated with metformin use, the metformin hydrochloride dose should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug as a 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's existing dose of metformin hydrochloride, according to the current treatment regimen. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's existing dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the existing doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Ingredients

Manufacturer
Aliko Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes who are suitable for combined treatment with Lina-gliptin and Metformin. Patients can manage blood sugar more effectively if this medication is taken alongside dietary and exercise therapies. In other words, this medication is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and extended-release metformin hydrochloride 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse effects associated with metformin use, the metformin hydrochloride dose should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug as a 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's existing dose of metformin hydrochloride, according to the current treatment regimen. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's existing dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the existing doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Precautions

This medication may rarely cause severe lactic acidosis and hypoglycemia, so caution is required. It should not be used in patients with severely impaired renal function, liver dysfunction, acute heart failure, or myocardial infarction. Patients with allergies to the ingredients of this medication or those with type 1 diabetes should also avoid its use. When used with other diabetes medications or insulin that can cause hypoglycemia, close monitoring of blood glucose changes is necessary, and dosage adjustments may be required. Lactic acidosis is a very serious side effect; if symptoms such as abdominal pain, myalgia, weakness, or dyspnea occur, notify a physician immediately. Regularly check renal function to ensure the safe administration of this medication, and take extra caution in elderly individuals or those at risk of impaired renal function. This medication should be temporarily discontinued before and after surgery or administration of radiographic iodine contrast, and resumed only after kidney function has recovered. Acute pancreatitis or skin blistering disorders may occur; if you experience severe abdominal pain or skin abnormalities during treatment, seek medical attention immediately. This medication should be taken during or after meals, and tablets should be swallowed whole without breaking, crushing, or chewing. Long-term use may decrease vitamin B12 levels, so it is advisable to check vitamin B12 status through blood tests. It is preferable to avoid this medication during pregnancy or breastfeeding, and patients planning a pregnancy should consult their physician. Interactions may occur when taken with other medications, so inform healthcare professionals of any other medications being taken. The safety and effectiveness of this medication in children have not been established, and dosing for elderly patients should consider renal function. In case of overdose, procedures should be taken to eliminate the drug from the gastrointestinal tract, and immediate treatment is necessary for lactic acidosis. This medication should be stored out of reach of children, away from moisture, and should not be transferred to other containers.

Side effects

nasopharyngitis, hypersensitivity reaction, angioedema, hives, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemia, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function tests, hepatitis, pruritus, erythema, rash, bullous pemphigoid-like condition, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot syndrome, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, speech disturbance, allergic rhinitis, exertional dyspnea, wet cough, runny nose, lung mass, arthralgia, osteoporosis, joint disease, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, androgenetic alopecia, hyperhidrosis, hair loss, dermatitis, anxiety, confusion, nocturia, dermatitis, hypertension, erectile dysfunction, goiter, vitreous hemorrhage, stomatitis, mediastinitis, rhinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, rectal bleeding, cheilitis, cavities, enteritis, gastritis, stomatitis, dizziness, sensory loss, drowsiness, chest pain, fever, facial swelling, hyperthermia, back pain, flank pain, osteoarthritis, limb pain, subdural effusion, headache, increased serum creatinine, nosebleed, nasal bleeding, hearing loss, dizziness, thyroid nodule, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Oval sustained release tablet, white to almost white, engraved with A501 on one side

Package unit

28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.